Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350

1.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, van Marwijk Kooy R, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ, Vellenga E, Löwenberg B.

Blood. 2019 Jan 10. pii: blood-2018-10-879866. doi: 10.1182/blood-2018-10-879866. [Epub ahead of print]

PMID:
30630862
2.

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.

Reedijk AMJ, Klein K, Coebergh JWW, Kremer LC, Dinmohamed AG, de Haas V, Versluijs AB, Ossenkoppele GJ, Beverloo HB, Pieters R, Zwaan CM, Kaspers GJL, Karim-Kos HE.

Leukemia. 2018 Dec 19. doi: 10.1038/s41375-018-0314-7. [Epub ahead of print]

PMID:
30568171
3.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2018 Dec 12. doi: 10.1038/s41375-018-0326-3. [Epub ahead of print]

PMID:
30542144
4.

IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.

Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui ML, de Vos Klootwijk LLE, Menezes RX, Çil M, Roemer MGM, Vermue E, Heukelom S, Zweegman S, Janssen JJWM, Ossenkoppele GJ, Schuurhuis GJ, Smit L.

Cell Rep. 2018 Dec 11;25(11):3021-3035.e5. doi: 10.1016/j.celrep.2018.11.062.

5.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group, Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group.

Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15698. [Epub ahead of print] No abstract available.

PMID:
30520018
6.

Measurable residual disease in acute myeloid leukemia using flowcytometry: approaches for harmonization/standardization.

Schuurhuis GJ, Ossenkoppele GJ, Kelder A, Cloos J.

Expert Rev Hematol. 2018 Nov 23. doi: 10.1080/17474086.2018.1549479. [Epub ahead of print]

PMID:
30466339
7.

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.

Morsink LM, Walter RB, Ossenkoppele GJ.

Blood Rev. 2019 Mar;34:26-33. doi: 10.1016/j.blre.2018.10.003. Epub 2018 Nov 1. Review.

PMID:
30401586
8.

Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands.

Kalin B, Pijnappel EN, van Gelder M, Visser O, van de Loosdrecht AA, Ossenkoppele GJ, Cornelissen JJ, Dinmohamed AG, Jongen-Lavrencic M.

Cancer Epidemiol. 2018 Dec;57:90-96. doi: 10.1016/j.canep.2018.09.007. Epub 2018 Oct 20.

PMID:
30347337
9.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.

10.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

11.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
12.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

13.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

14.

Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes.

van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, van de Loosdrecht AA.

Am J Hematol. 2017 Nov;92(11):E631-E634. doi: 10.1002/ajh.24867. Epub 2017 Aug 24. No abstract available.

15.

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?

Martiáñez Canales T, de Leeuw DC, Vermue E, Ossenkoppele GJ, Smit L.

Cancers (Basel). 2017 Jun 30;9(7). pii: E74. doi: 10.3390/cancers9070074. Review.

16.

The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.

van Solinge TS, Zeijlemaker W, Ossenkoppele GJ, Cloos J, Schuurhuis GJ.

Cytometry B Clin Cytom. 2018 Jan;94(1):151-158. doi: 10.1002/cyto.b.21539. Epub 2017 Aug 15.

17.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
18.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

19.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
20.

Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Witte BI, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2017 Feb;72:269-271. doi: 10.1016/j.ejca.2016.11.029. Epub 2017 Jan 2. No abstract available.

PMID:
28057399
21.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.

J Clin Oncol. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7.

PMID:
28056193
22.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

23.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

24.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

25.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

26.

Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.

PMID:
26798967
27.

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.

Ossenkoppele GJ, Janssen JJ, van de Loosdrecht AA.

Haematologica. 2016 Jan;101(1):20-5. doi: 10.3324/haematol.2015.139105. Review.

28.

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

Cremers EMP, Westers TM, Alhan C, Cali C, Wondergem MJ, Poddighe PJ, Ossenkoppele GJ, van de Loosdrecht AA.

Eur J Cancer. 2016 Feb;54:49-56. doi: 10.1016/j.ejca.2015.11.013. Epub 2015 Dec 22.

PMID:
26720403
29.

Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.

Verhagen HJ, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, Ossenkoppele GJ, Smit L.

Blood. 2016 Jan 28;127(4):458-63. doi: 10.1182/blood-2015-07-653840. Epub 2015 Nov 18.

30.

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.

Alhan C, Westers TM, Cremers EM, Cali C, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2016 Jul;90(4):358-67. doi: 10.1002/cyto.b.21333. Epub 2015 Dec 14.

31.

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Leukemia. 2016 Mar;30(3):658-65. doi: 10.1038/leu.2015.295. Epub 2015 Oct 27.

PMID:
26503643
32.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G.

Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169.

33.

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2016 Feb;30(2):439-46. doi: 10.1038/leu.2015.252. Epub 2015 Sep 16.

PMID:
26437777
34.

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2016 Mar;30(3):708-15. doi: 10.1038/leu.2015.255. Epub 2015 Sep 16.

PMID:
26373238
35.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Ruben JM, Visser LL, Heinhuis KM, O'Toole T, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

PLoS One. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219. eCollection 2015.

36.

Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2015 Nov;64(11):1419-27. doi: 10.1007/s00262-015-1741-1. Epub 2015 Jul 28.

37.

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.

Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17.

PMID:
26183645
38.

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans MC, Appelbaum FR, Erba HP, Estey EH.

Haematologica. 2015 Oct;100(10):e409-11. doi: 10.3324/haematol.2015.130013. Epub 2015 Jul 9. No abstract available.

39.

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.

de Leeuw DC, Verhagen HJ, Denkers F, Kavelaars FG, Valk PJ, Schuurhuis GJ, Ossenkoppele GJ, Smit L.

Leukemia. 2016 Mar;30(3):742-6. doi: 10.1038/leu.2015.160. Epub 2015 Jun 25. No abstract available.

PMID:
26108690
40.

Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered.

Zeijlemaker W, Kelder A, Wouters R, Valk PJM, Witte BI, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Br J Haematol. 2015 Oct;171(2):227-238. doi: 10.1111/bjh.13572. Epub 2015 Jun 24.

PMID:
26104974
41.

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study.

van der Poel MW, Mulder WJ, Ossenkoppele GJ, Maartense E, Hoogendoorn M, Wijermans P, Schouten HC.

Ann Hematol. 2015 Aug;94(8):1373-9. doi: 10.1007/s00277-015-2358-3. Epub 2015 Apr 14.

42.

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2015 Jun;100(6):e220-2. doi: 10.3324/haematol.2014.116657. Epub 2015 Mar 6. No abstract available.

43.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Cremers EM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):14-21. doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11. Review.

PMID:
25659726
44.

In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Oncoimmunology. 2014 Jul 3;3(7):e946360. eCollection 2014.

45.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M.

Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.

46.

MRD in AML: it is time to change the definition of remission.

Ossenkoppele GJ, Schuurhuis GJ.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):265-71. doi: 10.1016/j.beha.2014.10.008. Epub 2014 Oct 15. Review.

PMID:
25455276
47.

Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.

van Spronsen MF, Ossenkoppele GJ, Holman R, van de Loosdrecht AA.

Eur J Cancer. 2014 Dec;50(18):3198-205. doi: 10.1016/j.ejca.2014.09.016. Epub 2014 Oct 28.

PMID:
25454415
48.

Genomic amplification of MYC as double minutes in a patient with APL-like leukemia.

Poddighe PJ, Wessels H, Merle P, Westers M, Bhola S, Loonen A, Zweegman S, Ossenkoppele GJ, Wondergem MJ.

Mol Cytogenet. 2014 Oct 22;7(1):67. doi: 10.1186/s13039-014-0067-6. eCollection 2014.

49.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

PLoS One. 2014 Sep 22;9(9):e107587. doi: 10.1371/journal.pone.0107587. eCollection 2014.

50.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

Supplemental Content

Loading ...
Support Center